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Β-blockers (BB) are a primary treatment for chronic heart disease (CHD), resulting in prognostic and 
symptomatic benefits. Cardiac cell therapy represents a promising regenerative treatment and, 
for autologous cell therapy, the patients clinical history may correlate with the biology of resident 
progenitors and the quality of the final cell product. This study aimed at uncovering correlations 
between clinical records of biopsy-donor CHD patients undergoing cardiac surgery and the 
corresponding yield and phenotype of cardiospheres (CSs) and CS-derived cells (CDCs), which are 
a clinically relevant population for cell therapy, containing progenitors. We describe a statistically 
significant association between BB therapy and improved CSs yield and CDCs phenotype. We show 
that BB-CDCs have a reduced fibrotic-like CD90 + subpopulation, with reduced expression of collagen-I 
and increased expression of cardiac genes, compared to CDCs from non-BB donors. Moreover BB-CDCs 
had a distinctive microRNA expression profile, consistent with reduced fibrotic features (miR-21, miR-
29a/b/c downregulation), and enhanced regenerative potential (miR-1, miR-133, miR-101 upregulation) 
compared to non-BB. In vitro adrenergic pharmacological treatments confirmed cytoprotective and 
anti-fibrotic effects of β1-blocker on CDCs. This study shows anti-fibrotic and pro-commitment effects 
of BB treatment on endogenous cardiac reparative cells, and suggests adjuvant roles of β-blockers in 
cell therapy applications.
Cardiovascular diseases (CVDs), encompassing myocardial infarction (MI), heart failure, and stroke, are a lead-
ing cause of mortality and morbidity worldwide, accounting for 17 million deaths per year. The increased survival 
of MI patients has led to nearly epidemic heart failure and chronic heart disease (CHD), which is responsible 
for more than 30% of cardiovascular related deaths, according to the American Heart Association. MI imposes 
mechanical and neurohormonal challenges on cardiac walls, with the initial compensatory hypertrophy even-
tually evolving into maladaptive remodeling1. Among the many consolidated therapeutic strategies, β -blockers 
(BB) represent a primary pharmacological treatment. Beta-blockers are able to reverse the neurohormonal effects 
of the sympathetic nervous system, ensuring prognostic and symptomatic benefits. Specifically, BB have been 
shown in randomized trials to prolong survival by preventing arrhythmia, improving CHD symptoms and left 
ventricular ejection fraction (LVEF), and controlling ventricular rate2.
Although the mechanisms are still largely unknown, treatment with β -blocking agents induces reverse 
remodeling3 at both molecular and organ level4. The functional improvement observed in patients treated 
with β -blockers can be directly linked to changes in myocardial gene expression, as these drugs act as induc-
tors of a myocardial specific transcriptional program. As an example, molecular analyses on idiopathic dilated 
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cardiomyopathy patients treated with β -blockers showed changes in the β -adrenergic receptors expression, and 
specific regulation of key genes mediating myocardial function in responsive patients4. Moreover, miRNA expres-
sion in the heart has been shown to be influenced by β -blockers in physiological5 and pathological models6,7, and 
they have been shown to regulate β -adrenergic receptor expression8.
Among the most innovative therapeutic strategies for CVDs proposed in recent years, cardiac progenitor 
cell (CPC) therapy has received extensive attention as a promising treatment from pre-clinical and early clinical 
evidence suggesting the potential to directly regenerate cardiac tissue and to activate endogenous repair, particu-
larly for resident CPCs9–12. Despite strong transcriptomic similarities among the different resident CPC popu-
lations described in the literature13, the 3D model of cardiospheres (CSs) represents a unique niche-like in vitro 
microenvironment14,15, due to its tissue-like heterogeneity. CSs include cardiac progenitors, vascular progenitors 
and supporting mesenchymal cells, and display unique phenotypic, paracrine and regenerative features induced 
by the spontaneous 3D growth16–19. Recently CS-derived cells (CDCs) have successfully entered into cardiac cell 
therapy clinical trials, as a consolidated therapeutic cell product20,21. In addition, resident CPCs have been shown 
to be necessary for endogenous heart repair responses22.
As demonstrated for other adult stem cell types23–26, the medical history of the donor may affect endogenous 
regenerative abilities. Resident progenitors of most cardiovascular disease patients are naturally exposed in situ 
to multiple risk factors and elective drugs which are likely to modulate their biological features. This appears to 
represent a key issue to be considered in autologous strategies for the quality of the final cell product because 
cell number and regenerative potency are among the relevant factors affecting the success of cell therapy proto-
cols27–29. C-kit positive cardiac progenitor cells (C-kit + CPCs) respond differentially to β -adrenergic signaling 
in vitro based on their differentiation stage30. Moreover, studies suggest a positive correlation between mechan-
ical and pharmacological stress reduction and enhanced CPCs features. For example, niches of c-kit + CPCs are 
more abundant in vivo in the atria and apex31, which can be interpreted as a preference for microenvironments 
under lower contractile stress. In addition, mechanical unloading imposed on decompensated hearts by means 
of Left Ventricular Assist Device seems to be able to trigger favorable signaling leading to functional recovery 
of the myocardium, also through enhanced progenitor features32. Therefore, the impact of drug prescriptions 
and potential risk factors on resident cardiac progenitors requires careful investigation for developments and 
improvements of cardiac cell therapy protocols.
In the present study, we aimed to uncover correlations between clinical records of biopsy donor CHD patients 
undergoing cardiac surgery and the corresponding yield and phenotype of the clinically relevant CSs and CDCs 
therapeutic cell products. We detected a statistically significant positive correlation between β -blockers treat-
ment and successful cardiospheres isolation, and describe for the first time a significant difference in the phe-
notypic balance between cardiac and fibrotic/mesenchymal features within the final therapeutic cell product of 
cardiosphere-derived cells linked to β -blockers treatment.
Results
We collected in a database multiple anthropometric and clinical parameters of biopsy donors in order to deter-
mine possible correlations with the biological features of isolated CDCs (in terms of their quality and quantity as a 
cell product). The overall descriptive analysis of the population enrolled is presented in the first column of Table 1 
(baseline features), Supplementary Table 1 (surgical indications and operative data), Table 2 (pre-operative echo-
cardiographic parameters), and Table 3 (medical therapy). Patients undergoing elective major cardiac surgery 
were only enrolled in the study if atrial appendages could be safely harvested during the surgical procedure. 
Enrolled patients were 73% males, with a mean age of 73 ± 1.4, and a significant prevalence of hypertension and 
diabetes. Most of the patients had a preserved LVEF.
With respect to CSs isolation, we considered successful spheroid formation as a categorical parameter for 
the qualitative assessment of each biopsy, independent of its yield. We also considered the cumulative yield of 
CS-forming explant-derived cells (EDCs) per milligram of plated tissue for each biopsy as a continuous param-
eter. We have included the EDCs yield (from which the selective 3D cardiosphere stage is obtained) since it is a 
limiting step for the overall abundance of the final therapeutic cell product (i.e. CDCs)21. The unadjusted statisti-
cal analysis (Table 4) revealed a significant correlation between BB treatment in donor patients and: (i) the overall 
success in obtaining CSs from the explant (“Cardiospheres” parameter); (ii) the total cell number of CS-forming 
EDCs obtained from each biopsy (“Cumulative yield” parameter). The corresponding comparative analysis for 
the multiple parameters analyzed, according to BB treatment, is reported in Tables 1, 2 and 3, showing that the 
two patient populations (BB and non-BB) were homogeneous and consistent for most of the parameters.
To evaluate whether the correlation between CSs successful culture and BB treatment was independent of 
confounding variables, we performed a multivariable linear (versus cumulative EDCs yield; Table 5) and logistic 
(versus cardiospheres formation; Supplementary Table 2) regression analysis adjusting for valvular heart disease, 
which differed between BB and non-β -blocker (NBB) groups, emerging as a potentially confounding parameter 
(Table 1). This test showed that BB treatment was independently correlated only to CS formation and cumulative 
yield parameters.
Since BB treatment emerged as a strongly significant parameter in the overall success and yield of CS isolation, 
we investigated ex vivo the biological features of cells isolated from BB patients versus NBB. Β -blocker treatment, 
together with cellular yield, significantly affected EDCs efficiency in forming CSs. CSs yield was significantly 
higher for BB patients than NBB (Fig. 1a), considering only the few successful NBB explants. As the CS-formation 
process has been shown to be TGFβ -dependent16, this result was supported by significantly increased TGFBR2 
gene expression in BB cells (Fig. 1b).
The overall balance of key cellular subsets inside the CDCs population was analyzed by flow cytometry and 
was found to be different between BB and NBB patients. While the abundance of c-kit + cells was not affected, 
BB patients displayed a statistically significant lower percentage of CD90 + CDCs (Fig.1c,d)28,33,34. These data 
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suggest a potential reduction in CDCs prospective therapeutic efficacy, as recently described for the outcome of 
the CADUCEUS clinical trial28. In addition, the genes collagen I (COLI-A1) and III (COL3) were significantly 
differently expressed, with NBB-CDCs expressing higher levels of COLI-A1 and lower levels of COL3, com-
pared to CDCs from BB patients (Fig. 1e). The COL3/COLI-A1 ratio was thus significantly reduced in NBB cells 
(Fig. 1f), suggesting a shift towards a more fibrotic phenotype.
BB-CDCs displayed significantly higher expression of the cardiac specific genes MHC and Nkx2.5 (Fig. 2a); 
Nkx2.5 upregulation in cells from BB patients was also strikingly detectable at protein level by immunofluo-
rescence (Fig. 2b) suggesting overall a more cardiac-committed phenotype. Interestingly, smooth muscle actin 
Feature* Overall No β-blocker therapy Β-blocker therapy P†
Female 12/41 (29.3%) 5/19 (26.3%) 7/22 (31.8%) 0.744
Age, years 73 (64; 76) 74 (67; 76) 70 (61; 76) 0.402
Body mass index, Kg/cm2 27.0 (24.0; 28.4) 25.0 (23.7; 27.7) 27.5 (24.5; 28.5) 0.178
Diabetes mellitus 13/41 (31.7%) 6/19 (31.6%) 7/22 (31.8%) 1.0
Insulin-dependent diabetes mellitus 3/41 (7.3%) 0/19 3/22 (13.6%) 0.235
Hypertension 36/41 (87.8%) 17/19 (89.5%) 19/22 (86.4%) 1.0
Smoking history 0.652
 Never 25/41 (60.9%) 10/19 (52.6%) 15/22 (68.2%)
 Former 12/41 (29.3%) 7/19 (36.8%) 5/22 (22.7%)
 Current 4/41 (9.7%) 2/19 (10.5%) 2/22 (9.1%)
Atrial fibrillation 6/41 (14.6%) 3/19 (15.8%) 3/22 (13.6%) 1.0
Prior or recent acute myocardial infarction 12/41 (29.3%) 5/19 (26.3%) 7/22 (31.8%) 0.744
Recent acute myocardial infarction 8/41 (19.5%) 3/19 (15.8%) 5/22 (22.7%) 0.703
Surgical indication
 Ischemic heart disease 29/41 (70.7%) 12/19 (63.2%) 17/22 (77.3%) 0.493
 Valvular heart disease 21/41 (51.2%) 14/19 (73.7%) 7/22 (31.8%) 0.012
 Vascular disease 6/41 (14.6%) 2/19 (10.5%) 4/22 (18.2%) 0.668
 Other 2/41 (4.9%) 2/19 (10.5%) 0/22 0.209
Heart rate, bpm 75 (64; 86) 75 (65; 86) 75 (60; 87) 0.931
Systolic blood pressure, mmHg 130 (110; 132) 130 (110; 140) 120 (110; 130) 0.322
Diastolic blood pressure, mmHg 70 (70; 80) 70 (70; 80) 80 (70; 80) 0.598
ACEF score 1.5 (1.1; 1.8) 1.4 (1.1; 1.6) 1.5 (1.3; 1.8) 0.177
EuroSCORE II 3.1 (1.9; 6.5) 3.4 (1.9; 5.3) 2.7 (2.1; 9.6) 0.356
STS score 1.9 (1.0; 3.8) 2.2 (1.4; 3.6) 1.8 (0.9; 4.7) 0.632
Blood analysis
 Glucose, mg/dl 106 (89; 121) 98 (85; 119) 110 (95; 123) 0.364
 Total cholesterol, mg/dl 173 (142; 229) 187 (171; 237) 155 (131; 203) 0.123
 High density lipoprotein cholesterol, mg/dl 48 (36; 62) 48 (46; 58) 40 (35; 68) 0.413
 Creatinine, mg/dl 1.0 (0.9; 1.1) 1.0 (0.8; 1.1) 1.1 (0.9; 1.2) 0.371
 Estimated glomerular filtration rate, mL/min/1.73 m2 71 (57; 88) 75 (63; 92) 71 (57; 81) 0.388
 Erythrocyte sedimentation rate, mm 21 (11; 39) 25 (7; 44) 21 (19; 24) 1.0
Table 1.  Comparative analysis of baseline features of patients, overall or according to β-blocker therapy. 
*Reported as median (1st; 3rd quartile) for continuous variables and count/total (percentage) for categorical 
variables. †Computed with unpaired Mann-Whitney U test for continuous variables and Fisher exact test for 
categorical variables.
Variable* Overall No β-blocker therapy Β-blocker therapy P†
EDD, mm 51 (49; 54) 51 (47; 55) 52 (49.2; 53.7) 0.612
ESD, mm 33 (30; 36) 33 (29.5; 35.2) 33 (30; 37) 0.525
EDV, ml 123 (112; 141) 123 (102; 147) 129 (113; 139) 0.612
ESV, ml 44 (35; 54) 44 (33; 52) 44 (35; 58) 0.525
EF, % 63.4 (60; 69) 63.6 (58.8; 71.9) 63.1 (60.4; 68.5) 0.602
Table 2.  Comparative analysis of pre-operative echocardiographic parameters according to β-blocker 
therapy. EDD: end diastolic diameter. EDV: end diastolic volume. EF: ejection fraction. ESD: end systolic 
diameter. ESV: end systolic volume. *Reported as median (1st; 3rd quartile) for continuous variables and count/
total (percentage) for categorical variables. †Computed with unpaired Mann-Whitney U test for continuous 
variables and Fisher exact test for categorical variables.
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(SMA) expression, though not modulated at the transcriptional level (Fig. 2a), displayed a completely differ-
ent cytoplasmic organization, with BB-CDCs showing an homogenous cytoplasmic distribution, whereas 
NBB-CDCs had a cytoskeletal organization in fibers, reminiscent of a more fibrotic or mesenchymal pheno-
type (Fig. 2b). No differences were detectable in the expression of GATA4 and β -adrenergic receptor 1 (ADBR1) 
(Fig. 2a,b). Moreover, significantly higher expression of the pro-inflammatory cytokines IL-6 and IL-8 were 
detectable in NBB versus BB CDCs, while other cytokines and growth factors were expressed at similar levels 
(Supplementary Fig. S2a).
Since microRNAs have been described to play a role in cardiac pathological fibrosis35–39,cardiomyocyte pro-
liferation, progenitors commitment and differentiation40–43, TGF-β -mediated epithelial-to-mesenchymal transi-
tion44, and to correlate with CDCs therapeutic potential45,46, we selected a panel of miRNA genes to be analyzed 
in BB and NBB-CDCs20. Preference was given to those miRNAs showing altered expression due to β -blocking 
agents observed in other systems6,7,47–50. The relative expression of these miRNAs was quantified by realtime 
q-PCR. We performed hierarchical clustering analysis followed by non-parametric Kruskal-Wallis statistical test. 
This showed a significant difference between the two groups in terms of global expression profile of the shortlisted 
miRNAs. BB and NBB samples clustered separately as seen in the hierarchical dendrogram (Fig. 3a). Overall, the 
miRNAs related to progenitor cell survival or differentiation were significantly upregulated in CDCs from BB 
patients, whereas miRNAs involved in fibrosis were downregulated. Single comparisons of the expression of each 
miRNA in CDCs between BB and NBB patients showed that miR-1, miR-133 and miR-101 were significantly 
upregulated in BB patients (Fig. 3b,c), whereas miR-21, miR-29a/b/c and miR-146a were downregulated com-
pared to NBB (Fig. 3d,e), suggesting a reduced pro-fibrotic phenotype and increased cardiac commitment in BB 
cells compared to NBB.
Β -blocker drugs (such as athenolol, bisoprolol, metoprolol) are preferable β 1-receptor selective blockers in 
order to avoid the vascular and respiratory side effects of systemic β 2-blockade. Therefore, in order to investigate 
the mechanism of BB influence on CDC abundance and phenotype, we treated short-term BB and NBB CDCs 
in vitro with 10 μ M β 1-receptor agonist isoproterenol (ISO) or blocker metoprolol (METO) for 4 days, either 
in parallel or METO after ISO (4 + 4 days). Overall, ISO-treated CDCs contained a higher percentage of early 
apoptotic AnnexinV + cells, but this effect was significantly recovered when CDCs were subsequently treated 
with METO (Supplementary Fig. S3), suggesting a cytoprotective effect of β 1-blocking on CDCs. CDCs capac-
ity of forming secondary CSs was not affected by any of the short-term in vitro treatments (data not shown). 
Drug* Overall
No β-blocker 
therapy
Β-blocker 
therapy P†
Angiotensinogen converting 
enzyme inhibitor 18/41 (43.9%) 9/19 (47.4%) 9/22 (40.9%) 0.758
Aldosterone receptor antagonist 8/41 (19.5%) 2/19 (10.5%) 6/22 (27.3%) 0.249
Angiotensin II receptor antagonist 12/41 (29.3%) 6/19 (31.6%) 6/22 (27.3%) 1.0
Antiarrhythmic 4/41 (9.7%) 1/19 (5.3%) 3/22 (13.6%) 0.610
Aspirin 22/41 (53.6%) 11/19 (57.9%) 11/22 (50.0%) 0.756
Calcium-channel antagonist 10/41 (24.4%) 7/19 (36.8%) 3/22 (13.6%) 0.144
Diuretic 22/41 (53.6%) 9/19 (47.4%) 13/22 (59.1%) 0.538
Statin 26/41 (63.4%) 12/19 (63.2%) 14/22 (63.6%) 1.0
Table 3.  Comparative analysis of medical therapy of patients, overall or according to β-blocker therapy. 
*Reported as median (1st; 3rd quartile) for continuous variables and count/total (percentage) for categorical 
variables. †Computed with unpaired Mann-Whitney U test for continuous variables and Fisher exact test for 
categorical variables.
Variable* No β-blocker therapy Β-blocker therapy P†
Cardiospheres 7/19 (36.8%) 18/22 (81.2%) 0.005
Cumulative yield (EDCs/mg) 0 (0; 1,308) 3,319 (464; 6,012) 0.010
Table 4. Comparative analysis of cardiac progenitor cell isolation success and yield according to β-blocker 
therapy of donor patients. EDC: explant-derived cells. P1: first EDC collection. *Reported as median (1st; 3rd  
quartile) for continuous variables and count/total (percentage) for categorical variables. †Computed with 
unpaired Mann-Whitney U test for continuous variables and Fisher exact test for categorical variables.
Independent variable
Regression coefficient  
(95% confidence interval) P
Β -blocker 3450.14 (315.52; 6584.76) 0.032
Valvular disease 440.58 (− 2682.49; 3563.66) 0.775
Table 5.  Multivariable linear regression analysis for the association of EDCs cumulative yield and 
β-blocker therapy, adjusting for valvular disease.
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Interestingly, a partial but significant reduction in the CD90 + subpopulation was detectable in BB-CDCs after 
METO treatment compared to both untreated control and ISO (Fig. 4a–d). This is consistent with the lower 
percentage of CD90 cells isolated from BB versus NBB patients (Fig. 1c). Corresponding down-regulation of 
Thy1/CD90 gene expression levels was confirmed by realtime q-PCR (Fig. 4e). METO treatment was also able 
to significantly increase collagen I (COL-A1) and reduce collagen III (COL3) expression levels compared to ISO 
in all CDCs (Fig. 4e,f), consistent with the results from the comparative analysis between BB and NBB-CDCs 
(Fig. 1e,f). Finally, ISO treatment in vitro was associated to the same trends of significant upregulation of IL-6 and 
IL-8 expression levels observed in NBB-CDCs (Supplementary Fig. S2b).
Figure 1. Cardiac progenitor cells phenotype differ between β-blocker and non-β-blocker patients. 
Representative cell culture images and corresponding CS yield quantification (a) show how β -blocker (BB) 
patients were significantly more efficient in giving CSs compared to non β -blocker (NBB) patients (when 
considering only the few successful NBB explants) (n = 3 biological replicates). Consistently with the CS-
formation process being TGFβ -dependent, BB CPCs have significantly higher expression levels of TGFBR2 
(b) (n = 3–7). The immunophenotypes of BB and NBB-CDCs were significantly different in the abundance of 
the CD90 + subpopulation (c) (n = 4–9), also shown by the representative flow cytometry histograms (d). BB 
and NBB CDCs also significantly differed in their expression levels of collagen I (COL-A1) and III (COL3) (e) 
(n = 3–7), and in their expression ratio (f). *P < 0.05. **P < 0.01. Scale bars = 250 μ m.
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Discussion
In the scenario of autologous cardiac cell therapy clinical application, it is of great translational interest to assess 
how the medical background and pharmacological history of potentially eligible patients might influence the 
biology and the successful isolation of cardiosphere-derived cells (CDCs), currently among the most promising 
therapeutic cell products under clinical investigation9,20. We screened multiple medical records and CDCs ex 
vivo features for correlation discovery in order to identify predictive clinical parameters for their successful iso-
lation and optimal regenerative phenotype, and for the possible optimization of scale-up procedures for clinical 
translation.
We describe for the first time a significant positive correlation between BB treatment of donor patients and 
both successful CSs isolation, and CS-forming cells yield from primary explant cultures (Table 4). Our results 
also show profound differences in cells phenotype based on their isolation from either BB or NBB patients, 
Figure 2. Gene expression levels and immunofluorescence phenotype of CDCs from β-blocker (BB) and 
non-β-blocker (NBB) patients. BB-CDCs displayed significantly higher expression levels of the cardiac specific 
genes MHC and Nkx2.5 (a) compared to NBB (NBB n = 4, BB n = 8). Representative CDC immunofluorescence 
images (b) showing a higher Nkx2.5 nuclear expression in BB cells, consistently with the qRTPCR results. 
Albeit no differences between BB and NBB were detectable in its expression level, intracellular staining for SMA 
displayed significant differences at morphological and cytoskeletal levels between BB and NBB (b). ADRB1 was 
detectable in both BB and NBB-CDCs (b). *P < 0.05. Scale bars = 100 μ m.
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when considering only the minority of NBB explants that yielded CSs. In fact, a significantly faster and higher 
CS-forming capacity was detectable in BB explants compared to NBB (Fig. 1a). Moreover, an immunopheno-
typical shift of the described CDCs marker CD9051 was detectable between the two groups, with a significantly 
increased percentage of CD90 + cells in NBB (Fig. 1c). While the c-kit receptor has gradually become a highly 
debated cardiac progenitor cells marker22,52 and its specific role in CDCs biology and properties is negligible27,34, 
it has been recently reported that the expression of CD90/Thy1 is associated with a myofibroblast phenotype and 
lack of cardiovascular potential in CDCs33. Moreover, CD90 expression in injected CDCs negatively correlated 
Figure 3. MicroRNA expression in β-blocker versus non-β-blocker CDCs. Heatmap showing hierarchical 
clustering analysis of miRNAs that displayed significantly different euclidean distance (a). Analysis was 
performed using averaged euclidean distance. Comparative gene expression analyses of selected miRNAs 
between β -blocker (BB) and non β -blocker (NBB) CDCs (b–e). Bar graphs show the 2^− Δ ct value. N = 8–9 
experimental replicates, from 3 biological replicates each. *P < 0.05. **P < 0.01. ***P < 0.001.
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with infarct scar size reduction in the CADUCEUS clinical trial28. Interestingly, all acute ischemic patients in the 
trial received β -blocker therapy (complete protocol available at: http://www.sccelltherapy.net) and the success 
rate in CDC isolation procedures was almost complete (only one cell manufacturing failure, mean age of ischemic 
donor patients of 54 years old20). Albeit on a significantly older cohort (mean age of 70 years old, Table 1) of 
chronic heart disease patients, our observations are in line with these findings, and suggest β -blocking agents 
prescription as an adjuvant treatment for CVD patients eligible for autologous cell therapy with resident ther-
apeutic populations, such as CSs and CDCs. The higher percentage of CD90 + cells in NBB-CDCs could be 
also explained by the known proliferative effects exerted by chronic β -adrenergic stimulation on human cardiac 
fibroblasts53. To the best of our knowledge, no other surface marker has been described so far as significantly 
associated with influential therapeutic and biological features of the CDCs population.
Gene expression profiles revealed significantly higher collagen-IA (Fig.  1e), IL-6 and IL-8 levels 
(Supplementary Fig. S2), paralleled by decreased cardiac gene expression in NBB-CDCs (Fig. 2a), consistently 
with features of a fibroblast-enriched, and possibly more pro-inflammatory, cellular population. The expression 
Figure 4. Adrenergic pharmacological treatments in vitro affect CDC immunophenotype and gene 
expression levels. The immunophenotype of BB-CDCs after 4 days of pharmacological treatment with 
metoprolol (METO) showed a significant reduction in CD90 + cells, expressed as percentage of effect 
versus control (CTR), compared to isoproterenol (ISO)-treated cells (a), as also shown by the representative 
cytofluorimetry dot plots (b–d). Gene expression analyses by realtime PCR consistently showed significantly 
lower normalized gene expression levels of Thy-1 in METO-treated cells compared to both control (CTR) and 
ISO-treated cells (e). These latter also expressed significantly higher levels of Thy1 (e). Moreover, METO-treated 
CDCs expressed significantly lower levels of collagen I (COL-A1) and higher levels of collagen III (COL3) 
compared to both CTR and ISO-treated cells (e), as also shown by their expression ratio (f). (n = 4). *P < 0.05.
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of collagen III gene was instead decreased in NBB-CDCs, resulting in a reduced ratio of COL3/COL1 (Fig. 1f), 
known to be associated to fibrosis and adverse remodeling in the failing heart54. Interestingly, short-term in vitro 
pharmacological treatments with β 1-receptor agonist (ISO) and blocker (METO) molecules mimicked the basal 
profiles of BB and NBB CDCs, with cells exposed to higher adrenergic drive (i.e. NBB and ISO-treated) shar-
ing common trends of gene expression levels and CD90 + cells abundance (Fig. 4 and Supplementary Fig. 2). 
Moreover, METO treatment in vitro was associated with reduced apoptotic rate in CDCs (Supplementary Fig. 3).
Overall, our data suggest that excessive adrenergic stimulation may reduce viability of responsive cell pop-
ulations, including cardiosphere-forming cells, and drive progenitors towards a fibrotic-prone and possibly 
pro-inflammatory phenotype. Therefore, we can speculate that biological strengthening of resident cardiac 
cells, with intrinsic therapeutic potential, may be another mechanism underlying the beneficial effects of clinical 
β -adrenergic receptors blockade, in line with results from other authors on endothelial progenitor cell and prolif-
erating cardiogenic cells3,4. It has been reported that β 1-adrenergic stimulation of committed cardiac progenitors 
is responsible for early myocyte precursor loss30. Our data show that exposure to pharmacological β -blocking may 
exert pro-commitment effects. The favorable outcome of β -blockers treatment in the failing heart are depend-
ent on cardiomyocyte protection from apoptotic stimulation and, based on our findings, also on survival of an 
anti-fibrotic and potentially therapeutic endogenous pool. In this way β -adrenergic blockade seems to act as a 
pharmacological intervention able to enhance the reparative response in the failing heart.
It has been reported that cardiac progenitors are necessary for endogenous heart repair responses22, and sup-
posed features of enhanced function have been described to represent positive prognostic indices for coronary 
bypass patients55. In line with this evidence, a long term follow-up is ongoing in our study cohort to clarify 
whether efficient CSs isolation and their phenotype may be suggested as prognostic factors in chronic heart dis-
ease patients as well.
Among the many cellular and molecular pathways involved in cardiovascular diseases onset and progres-
sion, also a deranged miRNAs expression has been observed56. miRNA are well described post-transcriptional 
regulators of gene expression, participating in many pathophysiological mechanisms in the cardiovascular 
system56, as well as in progenitors biology and cardiomyocyte proliferation57,58. Additionally, miRNA expres-
sion can be affected by β -blockers treatment, and miRNAs can be directly involved in the β -adrenergic trans-
duction cascade5,7,8. A recent analysis showed that altered miRNAs expression due to MI could be reversed by 
β -blocker propranolol treatment in rats, suggesting that this drug can specifically revert MI-induced miRNA 
expression changes6. In our analysis, the expression profile of a selected panel of miRNAs was significantly differ-
ent between the therapeutic CDCs population expanded from either BB or NBB patients. Among the miRNAs 
analyzed, miR-1 and miR-133a were significantly upregulated in BB-CDCs. These muscle specific myo-miRs 
control skeletal and cardiac muscle differentiation and survival. The expression of miR-1 can enhance embry-
onic stem cells differentiation into cardiomyocytes59, and was also shown to be upregulated upon induction of 
cardiac differentiation of human cardiac progenitors isolated from fetal heart42. MiR-133a has been shown to 
exert a protective anti-apoptotic effect on cardiomyocytes exposed to oxidative stress, and transplantation of 
miR-133a-overexpressing CDCs promoted increased functional recovery in a murine MI model43. Moreover, 
cardioprotective miR-133a expression can be induced in vitro by β -blocker carvedilol treatment48. It also protects 
cardiomyocytes from apoptosis induced by constitutive activation of the β -adrenergic signaling7, highlighting its 
link to BB treatment and protective cardiac mechanisms. Moreover, miR-133 was shown to negatively regulate 
extra-cellular matrix deposition, thus reducing interstitial fibrosis in the heart60. Consistently with these obser-
vations, the increase of miR-133a in CDCs collected from BB-patients was associated with features of reduced 
pro-fibrotic phenotype and increased cardiac commitment. Accordingly, these features were also associated 
with increased miR-101 expression in BB-CDCs versus NBB. In fact, miR-101 has been shown to suppress car-
diac fibroblasts proliferation post-MI, with decreased collagen deposition and recovery of the impaired cardiac 
function37.
MiR-21 and the miR-29a/b/c family members are among the best characterized miRNAs involved in heart 
fibrosis and are highly expressed in fibroblasts38. Interestingly, they were all significantly downregulated in BB 
versus NBB-CDCs. High levels of miR-21 directly correlate with TGFβ -mediated heart fibrosis, and miR-21 was 
shown to be upregulated in cardiac fibroblasts after stress35. Our data suggest that the decreased expression of 
miR-21/miR-29 family observed in CDCs from BB patients might reflect the reduced proportion of pro-fibrotic 
cells within the BB-CDC population, which also correlated with a decreased percentage of CD90 + cells, overall 
suggesting a reduced fibrotic potential of BB-CDCs, which is desirable for any therapeutic cell product.
In conclusion, discovering and interpreting the connections between clinical-pharmacological features and 
molecular signals that may impair reparative processes or conversely improve cell survival represents a primary 
step for developing novel interventional therapeutic strategies aimed at enhancing myocardial healing. This study 
supports the possible predictive and adjuvant role of β -blocker treatment in cardiac cell therapy applications, as 
recently suggested for mesenchymal stem cell-based therapies61. It also suggests novel insights on the influence of 
BB treatments on the quality and abundance of the cardiac reparative cellular pool.
Besides negative inotropic action, multiple biological mechanisms have been described to be responsi-
ble for the beneficial effects of β -blockers therapy, such as antioxidant effects, increased cardiomyocyte resist-
ance to cell death and recovery of calcium handling dynamics48,62,63. Our data supports a protective effect of 
β -blockers treatment on the endogenous cardiac reparative pool, proposing for the first time an anti-fibrotic and 
pro-commitment mechanism at molecular level, confirmed by ex vivo mechanistic assessment of the effects of β 
1-adrenergic signaling on CDC biology. These results lay the foundations for future improvements of CDCs isola-
tion method, clinical assessment in cellular transplantation procedures, and for the enhancement of endogenous 
myocardial responses to injury mediated by β -blocking agents.
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Methods
Study population and design. This was a prospective observational study, approved by the pertinent ethics 
committee of Umberto I General Hospital - Sapienza University of Rome, and performed in conformity with 
the declaration of Helsinki. All patients provided written informed consent. A total of 41 patients undergoing 
cardiac surgery at one single academic medical center were included in our analysis. The inclusion criteria were 
as follows: 1) Age > 18 < 80 years, 2) Patients undergoing on-pump major cardiac surgery. The exclusion criteria 
were as follows: 1) life expectancy < 1 year; 2) presence of malignancies; 3) conditions precluding adherence to 
the protocol (7 patients excluded); 4) pregnancy; 5) enrollment in other clinical research trial; 6) patients unable 
or unwilling to give informed written consent; 7) BB treatment started less than 30 days before cardiac surgery 
or a proved non-compliance to BB therapy (2 patients excluded). A complete preoperative evaluation by a multi-
disciplinary team included demographic data, blood tests, 12-lead electrocardiography, and pharmacological 
therapy. Patients were considered under BB treatment if the drug was started at least 30 days before surgery. If no 
data about the length of BB treatment were available, patients were excluded from the study. In all patients a 2D 
Doppler echocardiography was performed as previously described64. LV end-diastolic and end-systolic volumes 
were calculated using the Teichholz method65.
Cell cultures. Surgical biopsies of left atrial appendages were collected at the time of venous cannulation 
from patients undergoing on-pump major cardiac surgery, and cultured as explant culture. CPCs were isolated 
with the standardized CS protocol, as previously described15,21,66. Briefly, after 4 weeks of explant outgrowth, 
explant-derived cells (EDCs) were collected every 7 days (up to 3 times from each explant), and seeded on poly- 
D-lysine (BD-Biosciences) coated wells (9000 cells/cm2) to obtain CSs. These were then collected and expanded 
on fibronectin (BD-Biosciences) coated surfaces as cardiosphere-derived cells (CDCs), and expanded for not 
more than two split rounds, depending on the variable yield of each patient. Phenotypic as well as molecular 
analyses on CS and CDCs have been performed on passages number 1 or 2 (first or second harvest from the 
explants culture). Secondary CSs (IICSs) were obtained by replating CDCs in CS-forming conditions. CS yield 
(normalized to growth surface) and dimensions were calculated 1 week after plating (averaging all harvests for 
each biopsy) from image analysis of at least 8 random fields of culture plates, by binary transformation and auto-
mated particle count with ImageJ software (NIH). Considering the significantly lower culture success and yield 
of non β -blockers biopsies, the number of available biological replicates could not always match that of cells from 
BB donors.
Pharmacological treatments. CDCs from four different patients were treated in vitro in media supple-
mented with 0, 1% FBS. Cells from each patient were cultured in parallel for 4 days with 10 μ M isoproterenol 
(ISO) (Monico) or 10 μ M metoprolol (METO), a selective β 1-receptor blocker (AstraZeneca), using cells cultured 
in media alone as control group. Furthermore, another group of cells was cultured for 4 days with 10 μ M ISO, 
and then with 10 μ M metoprolol for further 4 days. Regardless of the culture timing, media were changed every 
48 hours. Cells were collected after treatments and analyzed by flow cytometry and realtime qPCR, as described 
below, or plated from each condition on Poly-D-Lysine coated plates for CS formation assay.
Flow cytometry analysis. Cells were grown as CDCs and the percentage of cells expressing CD90 and 
c-kit markers was assessed by flow cytometry. CDCs from the first explant harvest and at passage 1 were used. 
Confluent CDCs were harvested with trypsin-EDTA, and stained with CD90-FITC (Dianova) and CD117 
(c-kit)-APC (eBioscience) antibodies, according to the manufacturer’s guidelines. For apoptosis detection, CDCs 
were stained with Annexin V/7-AAD kit (BD Pharmingen), according to the manufacturer’s guidelines. All 
acquisitions were performed using BD FACS-Aria II (BD Biosciences) and data were analyzed with FlowJo soft-
ware and DiVa Software (v6.1.1).
RNA extraction and qPCR. Total RNA was extracted using either the miRNeasy Mini or Micro Kit 
(Qiagen). RNA was quantified using a spectrophotometer. For gene expression analyses, cDNA was synthesized 
using 0.5 μ g RNA, with the High Capacity cDNA Reverse Transcription Kit (Life Technologies). Real-time qPCR 
was performed to assess gene expression, using Power SYBR Green PCR Master Mix (Life Technologies) and 
standard thermocycling conditions according to the manufacturer’s protocol. For microRNA analyses, quan-
tification was made using specific Taqman miRNA assays. Briefly 10 ng of RNA were converted in cDNA using 
sequence specific looped primers; each miRNA was then quantified by qPCR using specific Taqman miRNA 
assays and the Taqman Universal Master Mix no UNG (Life Technologies). The relative ratio versus control 
sample was calculated using the comparative Ct method (2^− Δ Δ Ct). The set of gene analyzed and the primers 
sequences are listed in Supplementary Table 3. GAPDH and HPRT1 (averaged Ct) were selected according to the 
Norm Finder software, as housekeeping genes for gene expression analyses67. For CDCs microRNA gene expres-
sion, U6 was used as internal control. The PCR data (delta-Ct value) were analyzed using MeV software (TM4 
Software Suite) to generate the heatmap.
Immunofluorescence. Cells were fixed for 10 minutes with 4% paraformaldehyde at 4 °C, permeabilized 
with 0.1% Triton X-100 (Sigma) in PBS with 1% BSA, then blocked in 10% goat serum, incubated overnight 
at 4 °C in 1% goat serum with primary antibodies, and then incubated for 2 hours at room temperature with 
Alexa-conjugated secondary antibodies (Invitrogen). Primary antibodies were: ADBR1 (Santa Cruz), α SMA 
(Sigma), GATA-4 and Nkx2.5 (both Abcam). Slides were mounted in ProLong Gold antifade reagent with DAPI 
(Life Technologies). Imaging was performed on a Nikon Eclipse Ni microscope equipped with VICO system and 
NIS-Elements AR 4.30.02 software.
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Statistical analysis. Descriptive analysis was based on median (1st quartile, 3rd quartile) for continuous 
variables, and count (percentage) for categorical variables, whilst bar graphs displaying mean ± standard error 
of the mean were used for illustrative purposes. Unadjusted inferential analysis was based on Mann-Whitney 
U, Kruskal-Wallis, and Spearman tests for continuous variables, and Fisher exact test for categorical variables. 
For microRNA analysis, clustering was performed setting average Euclidean distance and Kruskal-Wallis test 
to visualize significant genes (MeV software; TM4 Software Suite). Multivariable linear or logistic regression 
analyses were also conducted to adjust for potential confounders. Computations were performed with Stata 13 
(StataCorp), SPSS 20 (IBM) and GraphPad Prism 5 (GraphPad Software).
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